Loading
Genetic Factors in Colorectal Cancer / Ferroptosis and Cancer Prognosis · Journal article
Journal of Gastroenterology and Hepatology · August 12, 2026
Raises a question worth testing. It does not answer one.
This is a preclinical mechanistic study demonstrating that CCT2 knockdown reduces colorectal cancer cell growth and invasiveness in vitro and in vivo, and promotes CD8+ T cell activation by suppressing the JAK1–STAT3–PD-L1 axis. The work identifies a potential therapeutic target but provides no evidence of clinical efficacy or safety in patients, and relies on surrogate endpoints and animal models.
Mechanistic in vitro and in vivo study with bioinformatics and correlative analysis in archival tissues. Colorectal cancer cell lines, syngeneic or patient-derived xenograft mouse models, and archival tissue samples from CRC patients; focus on microsatellite-stable/proficient mismatch repair disease, though specific eligibility criteria not stated.. Intervention: CCT2 knockdown (method of knockdown not specified in abstract). Compared with: Control or wild-type CCT2 expression (comparison group implied but not explicitly detailed).
CCT2 expression is significantly increased in CRC tissues relative to normal tissue (analysis of public datasets; specific fold-change not reported) CCT2 knockdown inhibited CRC cell growth, invasiveness, and migration in vitro and in vivo A positive correlation between CCT2 and PD-L1 expression was observed in public datasets and clinical CRC patient samples
No quantitative effect sizes or p-values provided for cell proliferation, apoptosis, invasion, migration, or immune cytotoxicity assays
This work is at an early stage and does not provide evidence for clinical use. CCT2 emerges as a mechanistic target in immune evasion pathways, but therapeutic translation requires Phase 1–2 clinical trials and validation of safety and efficacy in patients.
Mechanistic study in cell lines and xenograft models identifying CCT2 as a regulator of immune escape; lacks clinical trial data or hard clinical outcomes to support therapeutic claims.
As stated by the source record.
This work is at an early stage and does not provide evidence for clinical use. CCT2 emerges as a mechanistic target in immune evasion pathways, but therapeutic translation requires Phase 1–2 clinical trials and validation of safety and efficacy in patients.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Background Colorectal cancer (CRC) is a major global health burden. While immune checkpoint inhibitors have greatly advanced cancer therapy, their therapeutic effects are unsatisfactory in microsatellite‐stable/proficient mismatch repair CRC. This study explored the molecular mechanisms underlying CRC immune evasion. Methods Bioinformatics analysis and machine learning were applied to screen key targets. Real‐time quantitative polymerase chain reaction (RT‐PCR) detected CCT2 and programmed cell death ligand 1 (PD‐L1) mRNA levels, and Western blot measured PD‐L1, STAT3, and p‐STAT3 protein expressions. Cell proliferation, apoptosis, invasion, migration, and immune cytotoxicity were assessed via 5‐ethynyl‐2′‐deoxyuridine (EdU), TUNEL, Transwell, wound healing, and lactate dehydrogenase (LDH) assays. ELISA was used to detect interferon‐γ (IFN‐γ) and tumor necrosis factor‐α (TNF‐α) secretion, and xenograft mouse models were established for in vivo verification, with immunohistochemistry detecting tumor PD‐L1 expression. Results This study identified CCT2 as a core gene of CRC. Analysis of public datasets revealed a significant increase in CCT2 expression in CRC tissues. CCT2 knockdown inhibited CRC cell growth, invasiveness, and migration in vitro and in vivo. A positive correlation between CCT2 and PD‐L1 expression was observed in public and clinical CRC patients. Furthermore, CCT2 knockdown promoted the activation and proinflammatory cytokine secretion of CD8 + T cells. Mechanistically, CCT2 knockdown diminished PD‐L1 expression and promoted activation of CD8 + T cells via the JAK1‐STAT3 signaling pathway. Conclusion CCT2 upregulation promoted immune escape of colorectal cancer via regulating the JAK1‐STAT3‐PD‐L1 axis, suggesting a promising role of CCT2 in CRC treatment.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.